1 year return (CAGR)
-27.10%
Arbonia AG Exchange (SW, CHF)
ARBN.SW
3.65
-0.05 (-1.35%)
IndustrialsBuilding Products & Equipment
Loading...
3 year return (CAGR)
-23.87%
5 year return (CAGR)
-29.71%
10 year return (CAGR)
-12.99%
Adobe 2026 Q3 – Is sentiment driving the price?
Read MoreMarketcap
253.23M
Price/Sales
0.21
Ent value
621.49M
Price/Book
0.35
Div yield
0.00%
Growth years
-
Div growth
-
FCF payout
-255.97%
Trailing P/E
2.79
PEG
-
Forward P/E
19.92
EPS growth
-
Stock information
What is a stock exchange? Operation, actors, examples
Read MoreStock chart
Loading...
Stock price data
| Open | 3.70 |
| Daily high | 3.80 |
| Daily low | 3.63 |
| Daily Volume | 484K |
| All-time high | 92.34 |
| 1y analyst estimate | 6.20 |
| Beta | 0.75 |
| EPS (TTM) | 1.31 |
| Dividend per share | 0.00 |
| Ex-div date | 29 Apr 2025 |
| Next earnings date | 3 Mar 2026 |
Downside potential
Loading...
Downside potential data
| ARBN.SW | S&P500 | |
| Current price drop from All-time high | -96.05% | -2.82% |
| Highest price drop | -96.19% | -56.47% |
| Date of highest drop | 8 Jul 2026 | 9 Mar 2009 |
| Avg drop from high | -65.85% | -10.64% |
| Avg time to new high | 111 days | 12 days |
| Max time to new high | 4894 days | 1805 days |
News
SpaceX’s latest Starship flight turned what sounded like science fiction into a live demo of cheaper, higher capacity access to orbit, and that ripples far beyond one private company. Lower launch cos...
November 15, 2026
If approved, Cosentyx® (secukinumab) will become the only IL-17A inhibitor for adolescents with moderate to severe HS in Europe1,2HS affects as many as one in 100 people worldwide,3 with more than hal...
November 13, 2026
Oil markets have quietly shifted from scarcity worries to surplus signals, and that change in the jet-fuel equation suddenly matters a lot more for airlines and air cargo carriers. Lower fuel costs ca...
November 13, 2026
GL Events has delivered a powerful 93.0% share price gain over the past 5 years, which naturally puts the spotlight on what investors are paying for its earnings today. With the stock last closing at ...
November 13, 2026
DISCLOSURE OF TRANSACTIONS IN OWN SHARES FROM NOVEMBER 6 TO 13, 2026 Paris – November 13, 2026 As part of the implementation of the treasury share buyback program authorized by the Shareholders’ Gener...
November 13, 2026
REGULATORY INFORMATIONParis, 13 November 2026 COMBINED GENERAL MEETING OF DECEMBER 4, 2026 Convening of the Ramsay Générale de Santé General Meeting Conditions of availability and consultation of the ...
November 13, 2026
Novartis will now approach regulators in a bid to expand Rhapsido’s label as analysts foresee a blockbuster future for the drug.
November 13, 2026
RemIND data show clinically meaningful responses through Week 52 across three most prevalent CIndU subtypes, including after switching from placebo at Week 241Twice as many Rhapsido-treated patients a...
November 12, 2026
Does Novartis (NVS) have what it takes to be a top stock pick for momentum investors? Let's find out.
November 12, 2026